AdBio partners is a VC firm with an entrepreneurial spirit, dedicated to life sciences & focusing on early-stage investments.
-
AndzonBio2 Strengthens Scientific and Strategic Capabilities with New Advisory Board and Leadership AppointmentMarch 4, 2026AndzonBio2 Strengthens Scientific and Strategic Capabilities with New Advisory Board and Leadership AppointmentREAD MORE
-
Tenpoint Therapeutics Ltd. Announces FDA Approval of YUVEZZITM, the First and Only Combination Eye Drop Approved to Treat PresbyopiaJanuary 29, 2026Tenpoint Therapeutics Ltd. Announces FDA Approval of YUVEZZITM, the First and Only Combination Eye Drop Approved to Treat Presbyopia
READ MORE
-
Tenpoint Therapeutics Secures $235 Million through Series B Stock Financing and Credit Facility to Accelerate Commercialization of YUVEZZI™January 29, 2026Tenpoint Therapeutics Secures $235 Million through Series B Stock Financing and Credit Facility to Accelerate Commercialization of YUVEZZI™
READ MORE
-
Calida Therapeutics, startup lauréate du « Golden Ticket » !January 29, 2026Calida Therapeutics, startup lauréate du « Golden Ticket » !
READ MORE
-
Agomab Announces Positive Phase 1 Interim Results with AGMB-447 in Healthy Participants and Initiation of Idiopathic Pulmonary Fibrosis CohortJanuary 9, 2026Agomab Announces Positive Phase 1 Interim Results with AGMB-447 in Healthy Participants and Initiation of Idiopathic Pulmonary Fibrosis Cohort
READ MORE
-
Agomab Announces Positive Topline Phase 2a Data for Ontunisertib in Fibrostenosing Crohn’s DiseaseNovember 24, 2025Agomab Announces Positive Topline Phase 2a Data for Ontunisertib in Fibrostenosing Crohn’s Disease
READ MORE
-
SparingVision Doses First Patient with SPVN20 for Advanced Retinitis Pigmentosa in NYRVANA TrialOctober 30, 2025SparingVision Doses First Patient with SPVN20 for Advanced Retinitis Pigmentosa in NYRVANA Trial
READ MORE
-
AndzonBio2 emerges from stealth mode and announces initial €3M seed funding to advance breakthrough treatments for neurological disordersOctober 23, 2025AndzonBio2 emerges from stealth mode and announces initial €3M seed funding to advance breakthrough treatments for neurological disorders
READ MORE
-
SparingVision Highlights Advances in Gene-Agnostic Gene Therapies at ESGCT 2025October 9, 2025SparingVision Highlights Advances in Gene-Agnostic Gene Therapies at ESGCT 2025
READ MORE
-
ARTHEx Biotech Upsizes Series B Financing Round to $87M to Advance Lead Program ATX-01September 17, 2025ARTHEx Biotech Upsizes Series B Financing Round to $87M to Advance Lead Program ATX-01
READ MORE
-
Integra Therapeutics secures €10.7 million investment round to advance development of FiCAT geneSeptember 9, 2025Integra Therapeutics secures €10.7 million investment round to advance development of FiCAT gene
READ MORE
-
EvlaBio raises €21 million Seed Funding to Develop a Monoclonal Antibody for the Treatment of Left Ventricular HypertrophyJuly 7, 2025EvlaBio raises €21 million Seed Funding to Develop a Monoclonal Antibody for the Treatment of Left Ventricular Hypertrophy
READ MORE
-
Tenpoint Therapeutics Ltd. Announces FDA Acceptance of New Drug Application for BRIMOCHOL™ PF for the Treatment of PresbyopiaJune 4, 2025Tenpoint Therapeutics Ltd. Announces FDA Acceptance of New Drug Application for BRIMOCHOL™ PF for the Treatment of Presbyopia
READ MORE
-
Augustine Therapeutics announces first patient dosed in Phase I for the treatment of Charcot-Marie-Tooth diseaseMay 27, 2025Augustine Therapeutics announces first patient dosed in Phase I for the treatment of Charcot-Marie-Tooth disease
READ MORE
-
SparingVision Presents PRODYGY data and Research Update in Two Oral Presentations at ASGCT 2025May 21, 2025SparingVision Presents PRODYGY data and Research Update in Two Oral Presentations at ASGCT 2025
READ MORE
-
Astraveus Enters Strategic Partnership with NecstGen to evaluate Lakhesys Benchtop Cell FactoryTM for CAR-T therapy manufacturingMay 6, 2025Astraveus Enters Strategic Partnership with NecstGen to evaluate Lakhesys Benchtop Cell FactoryTM for CAR-T therapy manufacturing
READ MORE
-
Tenpoint Therapeutics Ltd. Submits New Drug Application to U.S. FDA for BRIMOCHOLTM PF for the Treatment of PresbyopiaApril 9, 2025Tenpoint Therapeutics Ltd. Submits New Drug Application to U.S. FDA for BRIMOCHOLTM PF for the Treatment of Presbyopia
READ MORE
-
Augustine Therapeutics raises oversubscribed EUR 78 million / USD 85 million Series A financing roundMarch 24, 2025Augustine Therapeutics raises oversubscribed EUR 78 million / USD 85 million Series A financing round
READ MORE
-
Agomab Announces Positive Topline Phase 2a Interim Results for AGMB-129 in Fibrostenosing Crohn’s DiseaseMarch 12, 2025Agomab Announces Positive Topline Phase 2a Interim Results for AGMB-129 in Fibrostenosing Crohn’s Disease
READ MORE
-
Augustine Therapeutics appoints Gerhard Koenig as Chief Executive Officer as Company Prepares to Enter the ClinicFebruary 14, 2025Augustine Therapeutics appoints Gerhard Koenig as Chief Executive Officer as Company Prepares to Enter the Clinic
READ MORE
-
Saniona’s Joint Venture, Cephagenix, Secures Seed Funding from AdBio Partners and AbbVie VenturesJanuary 22, 2025Saniona’s Joint Venture, Cephagenix, Secures Seed Funding from AdBio Partners and AbbVie Ventures
READ MORE
-
Promotions and evolutions within the AdBio Partners’ management teamJanuary 13, 2025Promotions and evolutions within the AdBio Partners’ management team
READ MORE
-
Tenpoint Therapeutics Ltd. and Visus Therapeutics, Inc. Join Forces, Building the Next Era of Best - and First-in-Class Ophthalmic MedicinesDecember 18, 2024Tenpoint Therapeutics Ltd. and Visus Therapeutics, Inc. Join Forces, Building the Next Era of Best - and First-in-Class Ophthalmic Medicines
READ MORE
-
AndzonBio1 raises initial €3M in seed funding to advance breakthrough treatments for Cardiovascular, Renal and Metabolic DisordersOctober 29, 2024AndzonBio1 raises initial €3M in seed funding to advance breakthrough treatments for Cardiovascular, Renal and Metabolic Disorders
READ MORE
-
Agomab Announces $89 Million Series D Financing to Support Broad Fibrosis focused PipelineOctober 25, 2024Agomab Announces $89 Million Series D Financing to Support Broad Fibrosis focused Pipeline
READ MORE
-
ARTHEx Biotech Announces First Patient Dosed in Phase I-IIa ArthemiR™ Trial for Myotonic Dystrophy Type 1 (DM1)October 22, 2024ARTHEx Biotech Announces First Patient Dosed in Phase I-IIa ArthemiR™ Trial for Myotonic Dystrophy Type 1 (DM1)
READ MORE
-
Inserm Transfert and AdBio Partners launch AndzonBio®June 18, 2024Inserm Transfert and AdBio Partners launch AndzonBio®
READ MORE
-
AdBio Partners promotes Emma Gasol to PartnerJune 4, 2024AdBio Partners promotes Emma Gasol to Partner
READ MORE
-
AdBio Partners continues to strengthen its senior investment team with Emma Gasol as Director of InvestmentsOctober 16, 2023AdBio Partners continues to strengthen its senior investment team with Emma Gasol as Director of Investments
READ MORE
-
Agomab Raises $100 Million Series C to Advance Fibrosis-focused PipelineOctober 11, 2023Agomab Raises $100 Million Series C to Advance Fibrosis-focused Pipeline
READ MORE
-
AdBio partners appoints Laurence de Schoulepnikoff as Venture PartnerSeptember 4, 2023AdBio partners appoints Laurence de Schoulepnikoff as Venture Partner
READ MORE
-
Orikine Bio closes €5.5m Series Seed Financing with Sabadell Asabys and AdBioJuly 18, 2023Orikine Bio closes €5.5m Series Seed Financing with Sabadell Asabys and AdBio
READ MORE
-
SparingVision sells ex vivo GIRK technology to Tenpoint TherapeuticsJuly 12, 2023SparingVision sells ex vivo GIRK technology to Tenpoint Therapeutics
READ MORE
-
Tenpoint Therapeutics Launches with $70 Million Series A FinancingJuly 12, 2023Tenpoint Therapeutics Launches with $70 Million Series A Financing
READ MORE
-
AdBio partners strengthens its management team and promotes Clément Bertholet as PartnerJuly 11, 2023AdBio partners strengthens its management team and promotes Clément Bertholet as Partner
READ MORE
-
Astraveus raises €16.5 Million Series Seed round to advance the development of its automated, microfluidic Cell and Gene Therapy manufacturing platformJune 27, 2023Astraveus raises €16.5 Million Series Seed round to advance the development of its automated, microfluidic Cell and Gene Therapy manufacturing platform
READ MORE
-
Anoat Therapeutics raises €2M in seed funding to develop novel therapies for Cystic Fibrosis patients with high unmet medical needJune 19, 2023Anoat Therapeutics raises €2M in seed funding to develop novel therapies for Cystic Fibrosis patients with high unmet medical need
READ MORE
-
DiogenX raises €27.5M Series A financing to advance its first-in-class regenerative treatment for type 1 diabetes towards clinical developmentMay 10, 2023DiogenX raises €27.5M Series A financing to advance its first-in-class regenerative treatment for type 1 diabetes towards clinical development
READ MORE
-
ARTHEx Biotech Announces Closing of €42 M Series B Financing to Advance ATX-01, its Novel Treatment for Myotonic Dystrophy Type 1 (DM1)May 3, 2023ARTHEx Biotech Announces Closing of €42 M Series B Financing to Advance ATX-01, its Novel Treatment for Myotonic Dystrophy Type 1 (DM1)
READ MORE
-
French biotech Calida Therapeutics launches with seed funding, leveraging US academic research in thrombo-inflammatory disordersApril 6, 2023French biotech Calida Therapeutics launches with seed funding, leveraging US academic research in thrombo-inflammatory disorders
READ MORE
-
AdBio partners appoints Geoffroy de Ribains as Managing PartnerFebruary 23, 2023AdBio partners appoints Geoffroy de Ribains as Managing Partner
READ MORE
-
Agomab Reports Positive Phase 1 Results with AGMB-129, a GI-restricted ALK5 Inhibitor for Fibrostenosing Crohn’s DiseaseFebruary 2, 2023Agomab Reports Positive Phase 1 Results with AGMB-129, a GI-restricted ALK5 Inhibitor for Fibrostenosing Crohn’s Disease
READ MORE
-
Ribonexus appoints Steven Powell as CEODecember 14, 2022Ribonexus appoints Steven Powell as CEO
READ MORE
-
Univercells raises € 44 million in first close of its Series DOctober 19, 2022Univercells raises € 44 million in first close of its Series D
READ MORE
-
Tridek-One closes a €16 million financing round to develop first-in-class imune checkpoint agonistsSeptember 14, 2022Tridek-One closes a €16 million financing round to develop first-in-class imune checkpoint agonists
READ MORE
-
SparingVision Raises €75 Million Series B to Continue Building World-Leading Portfolio of Genomic Medicines for Ocular DiseasesSeptember 14, 2022SparingVision Raises €75 Million Series B to Continue Building World-Leading Portfolio of Genomic Medicines for Ocular Diseases
READ MORE
-
Agomab Therapeutics Selected as One of Fierce Biotech's "Fierce 15" Companies of 2022September 12, 2022Agomab Therapeutics Selected as One of Fierce Biotech's "Fierce 15" Companies of 2022
READ MORE
-
Thabor Therapeutics appoints Jérémie Mariau as CEOMay 17, 2022Thabor Therapeutics appoints Jérémie Mariau as CEO
READ MORE
-
AdBio partners welcomes Inserm Transfert as investor in second fund – AFB Fund IIMay 3, 2022AdBio partners welcomes Inserm Transfert as investor in second fund – AFB Fund II
READ MORE
-
Ribonexus receives €2M in deep tech financing from BpifranceApril 12, 2022Ribonexus receives €2M in deep tech financing from Bpifrance
READ MORE
-
Integra Therapeutics closes a new investment of €1.5-million with the addition of Columbus Venture Partners to seed roundMarch 29, 2022Integra Therapeutics closes a new investment of €1.5-million with the addition of Columbus Venture Partners to seed round
READ MORE
-
Integra Therapeutics appoints recognized geneticist George Church to its Scientific Advisory BoardFebruary 21, 2022Integra Therapeutics appoints recognized geneticist George Church to its Scientific Advisory Board
READ MORE
-
Univercells acquires SynHelix, entering into synthetic biology and the race to next-generation DNA synthesisJanuary 6, 2022Univercells acquires SynHelix, entering into synthetic biology and the race to next-generation DNA synthesis
READ MORE
-
Advent France Biotechnology becomes AdBio partnersDecember 7, 2021Advent France Biotechnology becomes AdBio partners
READ MORE
-
Integra Tx secures €4.5-million in funding from Advent France Biotechnology, Invivo Capital and Takeda VenturesDecember 2, 2021Integra Tx secures €4.5-million in funding from Advent France Biotechnology, Invivo Capital and Takeda Ventures
READ MORE
-
Aglaia Therapeutics becomes Ribonexus and signs exclusive license agreement with Pierre Fabre on small molecules targeting eIF4A, an innovative target in oncologyNovember 18, 2021Aglaia Therapeutics becomes Ribonexus and signs exclusive license agreement with Pierre Fabre on small molecules targeting eIF4A, an innovative target in oncology
READ MORE
-
Advent France Biotechnology launches its second fund with a first close at €86M ($102M)September 30, 2021Advent France Biotechnology launches its second fund with a first close at €86M ($102M)
READ MORE
-
New startup Aglaia Therapeutics raises €4M in seed funding to overcome resistance in oncology targeted therapiesSeptember 30, 2021New startup Aglaia Therapeutics raises €4M in seed funding to overcome resistance in oncology targeted therapies
READ MORE
-
Advent France Biotechnology creates Thabor Therapeutics and finances its seedSeptember 13, 2021Advent France Biotechnology creates Thabor Therapeutics and finances its seed
READ MORE
-
Geoffroy de Ribains promoted to partner at Advent France BiotechnologyJuly 2, 2021Geoffroy de Ribains promoted to partner at Advent France Biotechnology
READ MORE
-
Advent France Biotechnology appoints Sidonie Fabre as CFOJune 8, 2021Advent France Biotechnology appoints Sidonie Fabre as CFO
READ MORE
-
Adrien Clavairoly promoted to Senior Associate at Advent France BiotechnologyApril 29, 2021Adrien Clavairoly promoted to Senior Associate at Advent France Biotechnology
READ MORE
-
Three questions for Geoffroy de Ribains, operating partner at AFB and operating CEO at GAMUT TherapeuticsApril 22, 2021Three questions for Geoffroy de Ribains, operating partner at AFB and operating CEO at GAMUT Therapeutics
READ MORE
-
SparingVision Expands Novel Ocular Disease Pipeline with Acquisition of GAMUT TherapeuticsApril 19, 2021SparingVision Expands Novel Ocular Disease Pipeline with Acquisition of GAMUT Therapeutics
READ MORE
-
Advent France Biotechnology appoints Alejo Chorny, PhD, as operating partner and head of new Spanish operationsMarch 17, 2021Advent France Biotechnology appoints Alejo Chorny, PhD, as operating partner and head of new Spanish operations
READ MORE
-
Advent France Biotechnology participe au tour de table de Série B de 74M$ (61,5M€) d’AgomAb TherapeuticsMarch 10, 2021Advent France Biotechnology participe au tour de table de Série B de 74M$ (61,5M€) d’AgomAb Therapeutics
READ MORE
-
Advent France Biotechnology crée Gamut Therapeutics et finance son amorçageDecember 15, 2020Advent France Biotechnology crée Gamut Therapeutics et finance son amorçage
READ MORE
-
Advent France Biotechnology appoints Geoffroy de Ribains as operating partnerOctober 6, 2020Advent France Biotechnology appoints Geoffroy de Ribains as operating partner
READ MORE
-
Arthex secures €4.25M from Invivo Ventures and Advent France BiotechnologyJuly 23, 2020Arthex secures €4.25M from Invivo Ventures and Advent France Biotechnology
READ MORE
-
La start-up brestoise KALSIOM boucle son premier tour de financement de 2 millions d'eurosJune 9, 2020La start-up brestoise KALSIOM boucle son premier tour de financement de 2 millions d'euros
READ MORE
-
Wellium lève 2 millions d’euros auprès d’Advent France Biotechnology et de MACSF pour le développement de Leah, son outil de téléconsultationMarch 18, 2020Wellium lève 2 millions d’euros auprès d’Advent France Biotechnology et de MACSF pour le développement de Leah, son outil de téléconsultation
READ MORE
-
Alderaan Biotechnology raises €18.5M in Series A from Advent France Biotechnology (AFB) and MedicxiJanuary 9, 2020Alderaan Biotechnology raises €18.5M in Series A from Advent France Biotechnology (AFB) and Medicxi
READ MORE
-
Advent France Biotechnology participe au tour d’amorçage de 4,2 millions d’euros d’Augustine TherapeuticsDecember 16, 2019Advent France Biotechnology participe au tour d’amorçage de 4,2 millions d’euros d’Augustine Therapeutics
READ MORE
-
Urania Therapeutics closes a €3.5M initial seed roundNovember 6, 2019Urania Therapeutics closes a €3.5M initial seed round
READ MORE
-
Tridek‐One strengthens its executive teamOctober 2, 2019Tridek‐One strengthens its executive team
READ MORE
-
Tridek-One : Pacifier le système immunitaireJune 4, 2019Tridek-One : Pacifier le système immunitaire
READ MORE
-
Tridek-One raises € 3 million from Advent France Biotechnology and Advent Life SciencesApril 6, 2019Tridek-One raises € 3 million from Advent France Biotechnology and Advent Life Sciences
READ MORE
-
AgomAb Therapeutics Completes Euros 21m Series A FinancingApril 3, 2019AgomAb Therapeutics Completes Euros 21m Series A Financing
READ MORE
-
Anne Horgan joins Advent France Biotechnology as Partner and Arnaud Foussat as Operating PartnerSeptember 17, 2017Anne Horgan joins Advent France Biotechnology as Partner and Arnaud Foussat as Operating Partner
READ MORE
-
Advent France Biotechnology launches its first Life Sciences seed-fund with a first closing at €64.75M (USD68.5M)April 20, 2017Advent France Biotechnology launches its first Life Sciences seed-fund with a first closing at €64.75M (USD68.5M)
READ MORE